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Chemokine synergy-inducing molecules are emerging as regulating factors in cell
migration. The alarmin HMGB1, in its reduced form, can complex with CXCL12
enhancing its activity on monocytes via the chemokine receptor CXCR4, while the
form containing a disulfide bond, by binding to TLR2 or TLR4, initiates a cascade of
events leading to production of cytokines and chemokines. So far, the possibility that
the CXCL12/HMGB1 heterocomplex could be maintained in chronic inflammation was
debated, due to the release of reactive oxygen species. Therefore, we have assessed
if the heterocomplex could remain active in Rheumatoid Arthritis (RA) and its relevance
in the disease assessment. Monocytes from RA patients with active disease require a
low concentration of HMGB1 to enhance CXCL12-induced migration, in comparison
to monocytes from patients in clinical remission or healthy donors. The activity of the
heterocomplex depends on disease activity, on the COX2 and JAK/STAT pathways,
and is determined by the redox potential of the microenvironment. In RA, the presence
of an active thioredoxin system correlates with the enhanced cell migration, and with
the presence of the heterocomplex in the synovial fluid. The present study highlights
how, in an unbalanced microenvironment, the activity of the thioredoxin system plays a
crucial role in sustaining inflammation. Prostaglandin E2 stimulation of monocytes from
healthy donors is sufficient to recapitulate the response observed in patients with active
RA. The activation of mechanisms counteracting the oxidative stress in the extracellular
compartment preserves HMGB1 in its reduced form, and contributes to fuel the influx of
inflammatory cells. Targeting the heterocomplex formation and its activity could thus be
an additional tool for dampening the inflammation sustained by cell recruitment, for those
patients with chronic inflammatory conditions who poorly respond to current therapies.
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INTRODUCTION
The concomitant presence of pro-inflammatory cytokines (1, 2),
growth factors (3), prostaglandins (4), as well as chemokines (5)
orchestrate the characteristic features of Rheumatoid Arthritis
(RA). Several inflammatory chemokines, key regulators of
leukocyte migration (6), are present at high levels in RA
synovial fluid and tissue, with some of them accounting for
the recruitment of monocytes/macrophages (7), or indicating
disease activity (8). The analysis of the synovial cell infiltrate
shows that the number of monocytes/macrophages increases in
joints with active inflammation. Conversely, the reduction in the
amount of infiltrating monocytes is associated with successful
therapy, making this cell type a good biomarker of RA disease
activity (9). In particular, monocyte migration into human
synovium is driven by CXCL12 (10), while the organization
of lymphoid-like structures is controlled by CXCL13 and
CCL21 (11). An impressive amount of preclinical and clinical
evidence has progressively validated the role of chemokines
and their receptors in immune-mediated diseases (12), which
led to the development of several chemokine receptor blocking
agents, initially tested with success in RA pre-clinical models
(13). However, most of these competitive chemokine receptor
antagonists have disappointed when their efficacy was assessed
in clinical trials (5, 14).
The influx of monocytes into the inflammatory environment
favors the release of damage-associated molecular pattern
molecules (DAMPs), which are endogenous danger signals
released by necrotic cells or by immune cells stimulated by
pro-inflammatory mediators (15). High Mobility Group Box 1
(HMGB1) originally identified as chromatin-associated protein
(16), is a DAMP released by necrotic cells after tissue injury (17),
or secreted by activated inflammatory cells, and can be present
in the microenvironment in multiple redox forms. Whether and
how the redox status of HMGB1 is modulated by extracellular
catalysts was so far unknown, and have been elucidated in the
present study. The form containing a disulfide bond, between
cysteine 23 and 45, by binding to TLR2, or TLR4, initiates a
cascade of events leading to NF-κB translocation to the nucleus
and transcription of cytokine and chemokine genes (18, 19). On
the contrary, reduced HMGB1modulates autophagy through the
interactionwith the receptor for advanced glycation end products
(RAGE) (20).
Our group has described that, when fully reduced, HMGB1
can also form a complex with CXCL12, which is much
more powerful than CXCL12 alone in inducing the migration
of human monocytes via its selective receptor CXCR4. A
suboptimal concentration of CXCL12 that per se would not
induce monocyte migration, when combined with HMGB1 is
able to recruit monocytes in vitro and in vivo (21, 22). Recent
data demonstrate that the CXCL12/HMGB1 heterocomplex, via
CXCR4, can also coordinate tissue regeneration (23, 24).
CXCR4 is a G protein-coupled receptor (6) that initiates
a series of signaling events. The canonical signaling pathway
leads to chemotaxis and expression of specific genes (25). In
addition, CXCL12 binding to CXCR4 (26) activates the JAK-
STAT pathway, which contributes to the induction of cell
migration (27). The involvement of JAK in the signaling triggered
by several cytokines, interferons, and growth factors has driven
the development of several inhibitors for the treatment of
inflammatory disorders, including RA (28).
Among the principal mediators of inflammation in RA,
Prostaglandin E2 (PGE2) represents the target of non-steroidal
anti-inflammatory drugs and selective cyclooxygenase-2 (COX2)
inhibitors, such as celecoxib (29). The binding of PGE2 to its
receptors leads to the activation of the PI3K/AKT signaling
pathways, as well as to the production of cyclic AMP, promoting a
cascade of events that contributes to the unbalanced cellular and
molecular microenvironment (30), which occurs in RA.
The redox proteins Thioredoxin-1 (Trx) and Thioredoxin
reductase (TrxR) provide resistance against oxidative stress and
have been recently related to RA severity (31, 32). Of note, Trx
and TrxR are secreted by a variety of normal and neoplastic cells
(33, 34) and catalytically interact with proteins of the extracellular
face of plasmamembrane, including cytokine receptors, changing
their redox status and consequently their functions (35).
Although CXCL12, HMGB1, JAK, COX2, and PGE2 have all
been associated with RA, their exact mechanistic connections
are unclear. This has clinical relevance, as current treatments in
RA can achieve substantial benefit for the patient, and several
biomarkers can define clinical remission (36), but the final goal
of blocking inflammation is not achieved in a considerable
number of patients. This suggests that the different ligands and
receptors might be redundant, interconnected, or modulated by
undisclosed mechanisms.
The present study describes how in patients with active RA
the redox state of the environment, and the cell-signaling cascade
support the activity of the CXCL12/HMGB1 heterocomplex
on monocytes, sustaining the inflammatory condition. These
findings contribute to further understand RA pathology, how
the redox form of HMGB1 is controlled in the inflammatory
environment, and indicate novel therapeutic interventions for
those patients not responding to conventional treatments.
MATERIALS AND METHODS
Patients
A total of 41 RA patients undergoing routine disease assessment
at the Barts Health NHS Trust (London, UK) and at the
University Hospital (Zurich, CH) were enrolled in the study.
All patients fulfilled the American College of Rheumatology
1987 revised criteria for the classification of RA (37) and were
at different stages of the disease. Newly diagnosed patients
were treatment-naïve, while patients with long-standing RA
received standard treatment with conventional synthetic or
biologic disease modifying anti-rheumatic drugs (DMARDs) as
per local guidelines. Disease activity was assessed by using the
28-joint Disease Activity Score (DAS28) on the day of peripheral
blood or synovial fluid collection. Patients were divided into
two groups accordingly to the DAS28 cutoffs indicated by the
recommendations of the American College of Rheumatology
(38): DAS28 >3.2 for patients with active disease (moderate to
high disease activity), and DAS28<2.6 for patients in clinical
remission. We collected monocytes from 15 patients, synovial
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fluid from 26 patients, and plasma from 10 patients. The study
was approved by the Ethical Committees of the King’s College
Hospital (Rec. No. 05/Q0703/198), the East London & The City
Research Authority (Rec No. 07/Q0605/29), and of the Canton
Zurich (No. EK-515). Written informed consent was obtained
from every patient, and all samples were rendered anonymous.
Demographic, clinical and serological features of the patients
included in the study are reported in Table 1.
Blood, Synovial Fluid Collection, and Cell
Isolation
Sixteen milliliters of whole blood from RA patients was
collected in BD Vacutainer R© CPTTM Cell preparation tubes
(362782, BD Biosciences, San Jose, CA). Blood from healthy
donors (HD) was provided as buffy-coats by the Central
Laboratory of Swiss Red Cross (Basel, Switzerland). All samples
were processed within 24 h after blood withdrawal. Peripheral
blood mononuclear cells (PBMCs) were isolated using Ficoll-
hypaque density centrifugation. Monocytes, CD14+, were
isolated by positive immunoselection procedure (130-050-201,
CD14 MicroBeads, Miltenyi Biotec, Germany) according to
the manufacturer’s instructions. CD14+ monocytes from HD
were cultured for 6 h at a density of 1.7 x 106 cell/ml
in RPMI-1640 (31870) supplemented with 10% Fetal Bovine
Serum (16000-044), 1x non-essential amino acids (11140-
035), 1mM Sodium pyruvate (11360-039), 20mM GlutaMAX
(35050-038), 50µM β-Mercaptoethanol (31350-010), Penicillin
50 U/ml – Streptomycin 50µg/ml (15070-063), all from
Gibco ThermoFisher Scientific, Switzerland, in the absence or
TABLE 1 | Demographic, clinical, and serological features of the RA patients
included in the study.
Demographics Early RA
treatment-naïve
(n = 26 synovial
fluids)
DAS28<2.6
(n = 6)
DAS28>3.2
(n = 9)
Female % (n) 80.8% (21) 66.7% (4) 66.7% (6)
Age years (mean ± SD) 58.5 ± 14.7 51 ± 13.4 63.3 ± 13.0
BIOCHEMICAL AND CLINICAL PARAMETERS
ESR mm/h (mean ± SD) 46.6 ± 32.1 15 ± 9.4 44.4 ± 48.4
CRP mg/l (mean ± SD) 29.1 ± 36.2 0.0 ± 0.0 51.3 ± 106.7
RF + % (n)a 70.8% (17) 66.7% (4) 55.6% (5)
Anti-CCP + % (n)a 70.8% (17) N.D. N.D.
TJ/28 joints (mean ± SD) 10.9 ± 7.5 0 ± 0 14.1 ± 8.2
SJ/28 joints (mean ± SD) 7.8 ± 7.2 0.4 ± 0.9 15.6 ± 9.1
VAS GH patient (mean ± SD) 69.1 ± 26.8 N.D. N.D.
DAS28 (mean ± SD) 5.88 ± 1.39 2.2 ± 0.3 5.3 ± 1.3
DAS28 (range) 1.88 - 8.41 1.9-2.56 3.3-7
RA, Rheumatoid Arthritis; SD, Standard Deviation; ESR, Erythrocyte Sedimentation Rate;
CRP, C-Reactive Protein; RF, Rheumatoid Factor; CCP, Cyclic Citrullinated Peptide; TJ,
Tender Joints; SJ, Swollen Joints; VAS, Visual Analog Score; GH, Global Health; DAS,
Disease Activity Score; N.D., not determined.
aRF and CCP titres available for 24/26 patients.
presence of PGE2, at the final concentration of 1 nM, or IL-
6 and IL-1β at the final concentration of 20 ng/ml. For the
experiments using HD monocytes, COX2, or JAK2 inhibitors
were added to the cells together with PGE2 during the 6 h
culture. Synovial fluid samples were obtained by aspiration of
joint fluids from inflamed knees and stored at −80◦C until
usage.
Reagents
CXCL12 was synthesized using tBoc solid-phase chemistry
(39). Full-length HMGB1 was produced and stored in buffer
containing DTT (40) at the Institute of Research in Biomedicine
protein facility, or purchased (1690-HMB, R&D Systems,
Minneapolis, MN). PGE2 (14010) was purchased from Cayman
Chemical (Ann Arbor, MI). Recombinant human IL-6 (6206-
IL) and recombinant human IL-1β (201-LB) were purchased
(R&D Systems, Minneapolis, MN). TG101348 was from Selleck
Chemicals (S2736, Houston, TX), celecoxib (PZ0008), and
Auranofin (A6733) were purchased from Sigma-Aldrich (Saint
Louis, MO). Mouse anti-human CXCR4 APC-conjugated
(555976, BD Biosciences, San Jose, CA), mouse anti-human
CXCL12 (MAB350, R&D Systems, Minneapolis, MN), rabbit
anti-human HMGB1 (Ab18256, Abcam, Cambridge, UK),
mouse anti-HMGB1 (HM-901, HMGBiotech, Milan, Italy), and
rabbit anti-human thioredoxin (2429, Cell Signaling technology,
Leiden, The Netherlands).
Flow Cytometry Analysis
All antibodies were diluted 1:50, and monocytes stained with
anti-CXCR4-APC antibody for 20min at 4◦C. Samples were
acquired by using BD LSR Fortessa flow cytometer from BD
Biosciences (San Jose, CA) and analyzed with the FlowJo software
(FLOWJO LLC, Ashland, OR). The expression of CXCR4 was
calculated as ratio between the Mean Fluorescence Intensity
(MFI) detected in the stained samples on the unstained control
samples performed for each condition.
CXCR4 Oligomerization Determined by
PLA
CXCR4 homodimerization was assessed using the Duolink R©
in situ Detection Reagent Red (DUO92008) using the anti-
CXCR4 12G5 antibody diluted 1:100, and mouse PLUS
(DUO092001) and MINUS (DUO092004) probes, all from
Sigma-Aldrich (Saint Louis, MO). Briefly, monocytes from HD
were seeded in eight well chambers (94.6150.801, Sarstedt,
Nümbrecht, Germany), untreated or treated for 6 h with 1 nM
PGE2 or 1µM PGE2, fixed with 4% PFA in PBS for 10min
at 37◦C. All subsequent steps were performed according to
manufacturer instructions. Images were acquired with a Leica
TCS SP5 confocal microscope (Leica Microsystems, Heerbrugg,
Switzerland), using a 63x/1.4N.A. objective, and analyzed using
the open-source image analysis software Fiji (41).
Chemotaxis Assay
Migration of monocyte from RA patients or HD was analyzed
using 48-well Boyden chambers (Neuro Probe, Cabin John, MD)
with 5µm pore size polyvinylpyrrolidone-free polycarbonate
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membranes as previously described (42). Briefly, 5 x 104
monocytes were diluted in RPMI-1640 supplemented with
20mM Hepes, pH7.4, and 1% pasteurized plasma protein
solution (5% PPL SRK; Swiss Red Cross Laboratory, Berne,
Switzerland). Cells were then added to the upper wells. After
90min of incubation, the membrane was removed, washed on
the upper side with phosphate-buffered saline (PBS), fixed, and
stained. All assays were done in triplicate, and for each well
the migrated cells were counted at 100-fold magnification in
5 randomly selected fields (5HPF). Spontaneous migration was
determined in the absence of chemoattractant. The following
reagents were added to the chemotaxis buffer (42) to assess
their influence on monocyte migration: celecoxib at 1 nM and
TG101348 at 30 nM.
ELISA
Detection of Trx and TrxR reductase in RA plasma, synovial
fluids, and monocyte supernatants was performed by ELISA
following manufacturer instructions using the following kits:
Trx (EK1254, Boster Biological Technology Co., Pleasanton,
CA), and TrxR (ab192150, Abcam, Cambridge, UK). Detection
of PGE2 in supernatants of monocytes was performed using
Prostaglandin E2 EIA Kit-Monoclonal, following manufacturer
instructions (CAY514010, Cayman chemical, Ann Arbor, MI).
Monocytes fromHD, untreated or treated with 1 nMPGE2 for 6 h
were washed once with HBSS (14170120, Gibco ThermoFisher
Scientific, Switzerland) to remove the exogenous given PGE2. In
order to detect freshly synthetized PGE2, Trx, and TrxR, cells
were supplemented with HBSS and cultured for additional 2 h,
before collecting the supernatant.
Hybrid ELISA
For the detection of the heterocomplex between CXCL12 and
HMGB1, we performed a Hybrid ELISA as previously reported
(43). Optical density was measured at 450 nm. All procedures
were performed at room temperature.
Western Blot Analysis
Monocytes from HD cultured for 6 h in the presence or
absence of 1 nM PGE2, and freshly isolated monocytes from
RA patients were suspended at the density of 1.7 x 106
cell/ml in RPMI-1640 supplemented with 20mM Hepes (pH
7.4), 1% pasteurized plasma protein solution (5% PPL SRK;
Swiss Red Cross Laboratory, Berne, Switzerland), 1% protease
inhibitor (P8340, Sigma-Aldrich, St. Louis, MO), and 300 nM
HMGB1. Supernatants were collected after 30, 60, or 120min.
To preserve reduced residues, supernatants were alkylated
with 20mM iodoacetamide (C2H4INO) for 30min at room
temperature in the dark, and precipitated with ice-cold acetone.
The dry pellets were loaded in non-reducing sample buffer for
western blot analysis. The following reagents were added to the
chemotaxis buffer to assess their influence on HMGB1 redox
status: celecoxib at 1 nM, TG101348 at 30 nM, Auranofin at
2µM.
The proteins were blotted onto a PVDF filter Immobilion-
P (IPVH304F0, Millipore, Billerica, Massachusetts, MA), and
HMGB1 content was detected using the anti-human HMGB1
from HMGBiotech, and by incubation with the secondary anti-
mouse Goat horseradish peroxidase (HRP)-conjugate antibody
(1706516, Bio-Rad, Hercules, CA) following manufacturer
instructions. Super Signal (34077, Themo Scientific, Rockford,
IL) was used as luminol-based enhanced chemiluminescent
substrate for detecting HRP on the immunoblots. Reduced over
oxidized form of HMGB1 was calculated on the densitometric
values of the bands obtained.
Immunohistochemistry
Formalin-fixed, paraffin-embedded synovial samples were
obtained from RA patients fulfilling the American College
of Rheumatology 1987 revised criteria (37) undergoing
joint replacement, synovectomy, or arthroscopic biopsy.
Tissue samples were cut to 5µm slices and used for
immunohistochemistry (IHC) (44). To detect HMGB1 and
CXCL12, antigen retrieval was performed with Dako Target
Retrieval Solution at pH6 (S1699, Dako, Agilent, Santa Clara,
CA). To detect thioredoxin, antigen retrieval was performed
with 10mM Citric Acid, pH6. The concentrations of the primary
antibodies used were as follows: mouse anti-human CXCL12
(MAB350, R&D Systems, Minneapolis, MN; 0.5µg/ml), rabbit
anti-human HMGB1 (Ab18256, Abcam, Cambridge, UK;
1µg/ml), and rabbit anti-human thioredoxin (2429, Cell
Signaling technology, Leiden, The Netherlands, 1:600 dilution).
MACH4 Universal HRP polymer detection kit mouse/rabbit
(M4U534H) from Biocare Medical (Pacheco, CA) was used
according to manufacture instructions for the detection of
HMGB1 and thioredoxin. DAKO New Fuchsin Substrate System
(K698, Dako), was used for the detection of CXCL12 in double-
immunohistochemical analysis. Images were acquired using
a 40x/0.95N.A. Plan Apo objective on a Nikon Eclipse E800
upright microscope, equipped with the digital camera DXM1200
(Nikon, Egg, Switzerland), and using Act-1 software version 2.7
(Nikon).
Extracellular Flux Assays
All extracellular flux assays were performed using a Seahorse
Bioscience XF96 Analyzers. XF glycolysis stress test kit (103020-
100), and XF cell mito stress test kit (103015-100), both from
Seahorse Bioscience (Agilent, Santa Clara, CA), were used
according to the manufacturer instruction. Briefly, monocytes
from HD were cultured in Cell Tack-coated plates in the absence
or presence of 1 nMPGE2 for 6 h. Cells were washed andmedium
was replaced with the indicated medium for each specific
test. Drugs were added at the following final concentrations:
glucose (10mM), 2-D-glucose (50mM), oligomycin (1µM),
FCCP (0.5µM), Rotenone/Antimycin A (0.5µM). ECAR and
OCR values were normalized to the reading just before the first
drug injection.
Statistical Analysis
Correlation analysis between two groups of values was performed
using the Spearman’s correlation rank test, determining r-
and p-value. The statistical significance between two groups
was determined using the non-parametric Mann-Whitney test.
The statistical significance between more than two groups was
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calculated by using one-way or two-way ANOVA followed by
Bonferroni’s adjustment.
RESULTS
Monocytes From RA Patients With Active
Disease Require a Low Concentration of
HMGB1 to Enhance CXCL12-Induced
Migration
The presence of CXCL12 and HMGB1 at high concentrations in
the joints and the peripheral blood of patients with RA, could
favor the formation of the CXCL12/HMGB1 heterocomplex.
Since we previously described that the heterocomplex enhanced
monocyte migration on human monocytes from healthy donors
(HD) via CXCR4 (21), we evaluated its activity on monocytes
from patients with RA, which are exposed to pro-inflammatory
stimuli also in the circulation. Migration of freshly isolated
monocytes in response to different CXCL12 concentrations, or to
a suboptimal concentration of CXCL12 (10 nM) in combination
with different concentrations of HMGB1, was assessed in
vitro. Monocytes from patients with active RA, or in clinical
remission, did not differ in their capability to respond to CXCL12
(Figure 1A), and as demonstrated in monocytes from HD (21),
they did not migrate in response to HMGB1 alone (data not
shown). However, only in patients with active RA a 10-fold
lower amount of HMGB1 was required to induce an efficient
migration in response to the suboptimal concentration of
CXCL12 (Figure 1B). Moreover, we found a significant positive
correlation (r = 0.832, p = 0.0013) between the DAS28 score
and the capability of monocytes to migrate in response to the
heterocomplex formed with a low concentration of HMGB1
(Figure 1C). This response was not influenced by changes in the
expression of CXCR4 on cell surface, as flow cytometric analysis
showed no significant differences in CXCR4 expression between
monocytes from patients, regardless disease activity, and HD
(Figure 1D).
Identification of the Pathways Involved in
the Response to the CXCL12/HMGB1
Heterocomplex in RA
To evaluate whether, in RA patients with active disease, the
monocyte response to the heterocomplex depends on the activity
of pathways that are also target of therapy, we analyzed their
migration in the presence of celecoxib, the COX2 inhibitor. The
treatment totally abolished the enhanced capability of monocytes
from patients with active disease to respond to the heterocomplex
(Figure 1E), while it did not affect the migration profile of
monocytes from patients in clinical remission (Figure 1F).
Notably, both in patients with active disease or in clinical
remission, celecoxib did not influence the migration toward
CXCL12 alone.
As the JAK-blocking agents represent a novel therapeutic
strategy for treating RA patients not responsive to conventional
DMARDs, we investigated whether the inhibition of the
JAK/STAT pathway could prevent the response observed to
the heterocomplex. Monocytes from RA patients with active
disease lost their enhanced response to the heterocomplex when
cells were treated with a JAK2 selective inhibitor, TG101348,
while the migratory response to CXCL12 alone was not affected
(Figure 1G), nor the migration profile of monocytes from RA
patients in clinical remission (Figure 1H).
These data collectively indicate that the activity of the COX2
and of the JAK2-STAT pathways is necessary to induce the
enhanced migratory response to the heterocomplex we observed
in monocytes from patients with active RA.
The Response to the Heterocomplex in RA
Is Determined by the Redox Potential in
the Microenvironment and Depends on
Disease Activity
The functions of HMGB1, released in the extracellular space,
are regulated by different redox states, which confer to protein
the ability to form a complex with CXCL12 triggering CXCR4,
or to trigger RAGE and TLRs (43). In the microenvironment,
HMGB1 is progressively oxidized losing its capacity to form a
complex with CXCL12. As a lower HMGB1 concentration is
needed to obtain a synergistic effect on monocytes from RA
patients with active disease, we investigated the factors that could
be responsible for the maintenance of HMGB1 in the reduced
state. The thioredoxin system has been described to correlate
with disease severity in RA, but its role in the pathogenesis of
the disease was not clarified (32, 45). High levels of both Trx and
TrxR were present in plasma fromRA patients with active disease
(Figure 2A). Moreover, the plasma levels of TrxR positively
correlated with the DAS28 (TrxR: r = 0.781, p = 0.0172) and
Trx correlated with monocytes ability to migrate in response
to the heterocomplex formed by CXCL12 with 30 nM HMGB1
(Figure 2B; Trx: p = 0.0038 and r = 0.874; TrxR: p = 0.058 and
r = 0.666).
Primary monocytes from HD express good amount of
Trx that increases upon activation, and higher levels of Trx
are present in unstimulated monocytes from patients affected
by pathologies such as autoinflammatory diseases (46). We
therefore hypothesized that in RA patients with active disease,
the thioredoxin system maintains HMGB1 in the reduced
form, which binds CXCL12 enhancing its activity. Indeed,
depending on the DAS28 score, monocytes from RA patients
showed a different degree of oxidative capacity, with the
reduced form of HMGB1 preserved for a prolonged period
of time, when exposed to the supernatant of monocytes
from patients with the higher DAS28 (Figure 2C). These data
are in agreement with the correlation we observed between
migration induced by the heterocomplex and the DAS28 score
(Figure 1C).
Notably, HMGB1, CXCL12, and Trx were all present in the
same area of the synovial membranes of RA patients (Figure 2D).
In particular, synoviocytes, infiltrating cells, and endothelial cells
all expressed high levels of Trx. The heterocomplex was also
detected, at different levels, in the synovial fluid of patients with
active disease (Figure 2E), and it positively correlated with local
Trx and TrxR concentrations (Figure 2F; Trx: p < 0.0001 and
r = 0.784; TrxR: p= 0.001 and r = 0.718, respectively).
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FIGURE 1 | Migration induced by CXCL12 and the CXCL12/HMGB1 heterocomplex in monocytes from patients with RA. (A) Migration of monocytes from patients
with RA in response to CXCL12 alone. (B) Migration of monocytes from 6 RA patients with DAS28>3.2, 6 RA patients in clinical remission, and 5 HD in response to a
suboptimal dose of CXCL12 in the absence or presence of increasing concentrations of HMGB1. (C) Linear regression analysis performed between the DAS28 index
and the number of monocytes from RA patients migrated in response to the heterocomplex formed with 30 nM HMGB1. (D) Relative mean fluorescence intensity of
CXCR4 expression on freshly isolated monocytes from HD or form patients with RA. (E-F) Migration of monocytes from RA patients with DAS28>3.2 (E) or
DAS28<2.6 (F) in response the heterocomplex formed by a suboptimal dose of CXCL12 and increasing concentrations of HMGB1, in the presence or absence of the
COX2 inhibitor celecoxib. (G,H) Migration of monocytes from RA patients with DAS28>3.2 (G) or DAS28<2.6 (H) in response to the heterocomplex formed by a
suboptimal dose of CXCL12 and increasing concentrations of HMGB1, in the presence or absence of the JAK2 inhibitor (TG101348). In panels (E–H) control
migrations were performed with a suboptimal or an optimal concentration of CXCL12 alone (10 and 100 nM, respectively). All data are presented as mean±SEM of
migrated cells in 5HPF in at least 3 independent experiments performed with cells from different donors. *p < 0.05, **p < 0.01, ****p < 0.0001 using two-way ANOVA
plus Bonferroni’s adjustment or Mann-Whitney test.
PGE2 Stimulation of Monocytes From HD
Recapitulates the Response of Monocytes
From Patients With Active RA
The exposure of monocytes to pro-inflammatory mediators
in the bloodstream is a common characteristic of patients
with autoimmune diseases, and could be responsible for the
activity of the heterocomplex we have observed in monocytes
from patients with active RA. Therefore, we treated monocytes
from HD with different pro-inflammatory stimuli (IL-1β, IL-6,
or PGE2) and tested their ability to migrate in response
to CXCL12 or to the heterocomplex. While we did observe
a significant reduction in cell migration in response to
CXCL12 and to the heterocomplex when monocytes were
treated with IL-1β or IL-6 (Supplementary Figure 1), monocytes
exposed to 1 nM PGE2 recapitulated the responses observed in
monocytes from RA patients with active disease (Figures 3A,B
and Supplementary Figure 1D). Of note, in monocytes freshly
isolated from blood, part of the CXCR4 is internalized and
Frontiers in Immunology | www.frontiersin.org 6 September 2018 | Volume 9 | Article 2118
Cecchinato et al. CXCL12/HMGB1 Heterocomplex Activity in RA
FIGURE 2 | Extracellular redox changes in RA prevent HMGB1 oxidation and promote the heterocomplex formation. (A) Plasma levels of Trx and TrxR in RA patients
with DAS28>3.2 (n = 4) or in clinical remission, DAS<2.6 (n = 5). Statistical analysis performed using the Mann-Whitney test (*p < 0.05). (B) Regression analysis
performed between the levels of Trx or TrxR and the number of monocytes from RA patients migrated in response to the heterocomplex formed with 10 nM CXCL12
and 30 nM HMGB1 (Trx: p = 0.0038 and r = 0.874; TrxR: p = 0.058 and r = 0.666). (C) Analysis of the redox status of HMGB1, at different time points after
exposure to the supernatant of monocytes from RA patients with distinct DAS28 scores, performed by Western blot. Reduced over oxidized form of HMGB1 was
calculated on the densitometric values of the bands obtained from the experiments performed with supernatants of monocytes from 3 RA patients. (D) Representative
images of the immunohistochemical analysis performed on the synovial membrane of RA patients with active disease, in three different fields. Panels on the left:
expression of CXCL12 (red) and HMGB1 (brown); panels on the right: expression of Trx (brown). All images at 40x magnification (scale bar: 50µm). (E) Presence of
the heterocomplex in the synovial fluids of RA patients with active disease, assessed by hybrid ELISA. The dotted line represents the median value. (F) Linear
regression analysis performed between the levels of Trx or TrxR present in the synovial fluid and the amount of the heterocomplex detected by ELISA (p < 0.0001 and
r = 0.784, p = 0.001 and r = 0.718, respectively).
is re-expressed on the cell surface upon culture. The higher
surface expression of CXCR4 in culturedmonocytes compared to
freshly isolated cells shifts their responsiveness to lower CXCL12
concentrations, thus changing accordingly the suboptimal
concentration of the chemokine. The enhanced response to
the heterocomplex, we observed in monocytes cultured in the
presence of PGE2, was not due to changes in the expression of
CXCR4, as assessed by flow cytometry (Figure 3C), nor in the
frequency of CXCR4 homodimers on the cell surface, known
to increase at high PGE2 concentrations, quantified by confocal
microscopy using the proximity ligation assay (Figure 3D). The
PGE2 treatment did not alter the expression of TLR2 and TLR4,
while RAGE was never detected on the surface of untreated or
treated monocytes (data not shown).
The stimulation with 1 nM PGE2 induced also the release of
picogram amounts of PGE2 (207 ± 86 pg/ml; mean±SEM) in a
feed-forward loop, in line with the observation that the COX2
inhibitor affects monocytes responses in patients with active
disease. Indeed, celecoxib abolished in a similar manner the
response of monocytes from HD pre-treated with PGE2, without
affecting the response to CXCL12 alone (Figure 3E). Moreover,
also the JAK2 selective inhibitor abolished the response of
monocytes from HD pre-treated with PGE2 (Figure 3F). As
shown in Figure 3G, supernatants of monocytes from HD pre-
treated with PGE2 contained significantly higher levels of Trx
and TrxR, than untreated monocytes and, similarly to what
observed in RA patients, HMGB1 was preserved in the reduced
formwhen exposed to supernatant from PGE2 treatedmonocytes
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FIGURE 3 | Monocytes from HD treated with 1 nM PGE2 recapitulate the response of monocytes from RA patients with active disease. (A) Migration of monocytes
(n = 5) untreated or treated with PGE2 in response to a suboptimal dose of CXCL12 in the absence or presence of increasing concentrations of HMGB1. Data are
presented as mean±SEM of migrated cells in 5HPF. (B) Migration of HD monocytes untreated or treated with PGE2 in response to CXCL12 alone. (C) Relative mean
fluorescence intensity of CXCR4 expression on HD monocytes untreated or treated with PGE2. Statistical analysis was performed using the Mann-Whitney test. (D)
Relative mean fluorescence intensity of CXCR4 oligomerization, determined by PLA, in HD monocytes untreated or treated with 1 or 1,000 nM PGE2. Statistical
analysis was performed using the one-way ANOVA plus Bonferroni’s adjustment: ****p<0.0001. (E) Migration of monocytes from HD treated with PGE2 in response to
CXCL12 or the heterocomplex, in the presence (n = 4) or absence (n = 6) of the COX2 inhibitor celecoxib. (F) Migration of monocytes from HD treated with PGE2 in
response to CXCL12 or the heterocomplex, in the presence (n = 3) or absence (n = 3) of the JAK2 inhibitor (TG101348). Data in panels (A,B,E,F) are presented as
mean±SEM of migrated cells in 5HPF, in at least three independent experiments, and were analyzed using two-way ANOVA plus Bonferroni’s adjustment: **p < 0.01,
***p < 0.001, ****p < 0.0001. (G) Levels of Trx and TrxR in supernatant of monocytes (n = 11) untreated or treated with PGE2. Statistical analysis was performed with
the Mann-Whitney test (**p < 0.01). (H) Analysis of the redox status of HMGB1, at different time points after exposure to the supernatant of monocytes from HD,
untreated or treated with PGE2, and in the presence of Auranofin, celecoxib or TG101348 was performed by Western Blot. Representative images on the left panels.
Reduced over oxidized form of HMGB1 was calculated on the densitometric values of the bands obtained from the experiments performed with supernatants of
monocytes from 3 HD. Data are presented as mean±SEM, and were analyzed using the Mann-Whitney test (**p < 0.01). (I) Glycolytic metabolism of monocytes from
6 HD untreated or treated with PGE2, expressed as extracellular acidification rate (ECAR) in mpH/min. Statistical analysis was performed with the Mann-Whitney test
(*p < 0.05).
(Figure 3H). To test the role of the thioredoxin system in the
regulation of the HMGB1 redox status in the extracellular space,
we specifically inhibited the TrxR activity in monocytes from
HD pre-treated with PGE2. Indeed, the TrxR inhibitor Auranofin
led to a fast oxidation of HMGB1, similarly to what observed in
the supernatant of untreated monocytes, proving the relevance
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of the thioredoxin system in the modulation of the redox status
of HMGB1. Both celecoxib and the JAK2 selective inhibitor,
TG101348 promoted HMGB1 oxidation in the supernatant of
monocytes pre-treated with PGE2 (Figure 3H).
Monocytes exposed to PGE2 showed a reduced glycolysis,
whereas their oxygen consumption was not altered (Figure 3I
and Supplementary Figure 2), suggesting also a metabolic
reprogramming aimed at counteracting the acidification of the
extracellular space induced by the inflammatory stimulus.
DISCUSSION
This study has focused on the interaction of CXCL12 and
HMGB1 in RA, in which the individual contribution of different
pro-inflammatory mediators is yet not fully understood. The
response of peripheral monocytes to the heterocomplex formed
with low concentration of HMGB1 can be maintained in RA by
the activity of essential players: the PGE2/COX2 pathway, the
JAK/STAT pathway, and the thioredoxin system, all associated to
active disease.
The relevance of molecules that can synergize with
chemokines has never been evaluated on human leukocytes from
patients with inflammatory disorders. The first indications of
synergy between chemokines came with the discovery of CXCL4
as amplifier of CCL5 activities (47), of several chemokines as
enhancers of CCL19- and CCL21-induced responses (48), and
of CXCL10 as amplifier of CCL22 activities (49). Some years
later, a model of human atherosclerosis showed how crucial
is disrupting the formation of a chemokine-heterocomplex. A
small peptide disrupting the CXCL4/CCL5 heterocomplex was
able, alone, to reduce the formation of atheromatic plaques
(50). We demonstrated a functional synergism between CXCL12
and the alarmin HMGB1 in a mouse model of sterile tissue
damage. Inhibition of the formation of the heterocomplex,
obtained with glycyrrhizin, resulted in a significant reduction
of monocytes influx into the muscle (21). So far, no data
were available on the presence of heterocomplexes in human
pathology, nor their activity was tested on leukocytes from
patients.
The present work shows that monocytes from patients with
active RA respond to the heterocomplex CXCL12/HMGB1
formed in the presence of low HMGB1 concentrations. In HD
and RA patients in clinical remission, the presence of low
HMGB1 concentrations is not sufficient to enhance CXCL12-
induced responses. These novel data indicate that the synergism
between these molecules could influence the progression of
the disease by enhancing the migration of monocytes to
site of inflammation. The association between PGE2 and RA
inflammatory processes is well-known, also due to the ability of
PGE2 to promote the expression of pro-inflammatory cytokines
(51). In fact, many inhibitors of PGE2 biosynthesis have been
developed and show good pharmacological efficacy (29). Here
we demonstrate that the COX2 inhibitor, celecoxib, can convert
the response to the heterocomplex of monocytes from patients
with active disease, to the response observed in patients in clinical
remission or in HD.
The activation of JAK-STAT signaling cascade is important
for the function of CXCR4 (52), the selective receptor used by
the heterocomplex. Inhibitors of the JAK-STAT signaling cascade
have also been used in the treatment of RA because of the
crucial role of JAK in the signaling of the type I and type II
inflammatory cytokine receptors (28, 53). JAK2 phosphorylation
has been shown to be higher in monocytes from RA patients
with active disease as compared to patients in remission (54).
JAK2 activation in monocytes from RA patients with active
disease is also required for achieving the response to the
heterocomplex. Nonetheless, JAK2 inhibition does not modify
the activity of the heterocomplex when high concentrations of
HMGB1 are applied, suggesting that in this condition, CXCR4
triggering can lead to the activation of additional pathways.
The concomitant activation of the COX2/PGE2 and JAK/STAT
pathways is able to promote the response to the heterocomplex
formed with low concentration of HMGB1, and provides
evidence of the intricate interplay between these two signaling
cascades in promoting monocyte migration in patients with
active RA.
Inflammatory conditions are associated with the release of
Reactive Oxygen Species (ROS), which alters the redox status
of the microenvironment. Our data suggest that the oxidative
stress induced by the exposure of monocytes to PGE2 is balanced
by the release of Trx and TrxR, and by a reduction in the
glycolytic metabolism in order to counteract the acidification
of the extracellular space. In active RA, we have observed the
release of high levels of Trx and TrxR, produced by blood vessels
and synoviocytes, which represents an attempt of reducing the
oxidative stress. Nonetheless, this pathway becomes detrimental
when HMGB1 is released, because the protein is preserved in its
reduced form, contributing to fuel the income of inflammatory
monocytes into the synovium (Figure 4). Of note, reduced
HMGB1 is not sufficient to trigger migration via CXCR4, but
needs the concomitant presence of CXCL12. Additional proteins
associated with the membrane and important for cell adhesion,
such as the integrin α4, could be also affected by changes in the
redox status of the microenvironment and further contribute to
the enhanced migration (55).
The histologic features of the synovial membrane in patients
with RA can vary from follicle-like-structures rich phenotype
to a more diffuse inflammatory infiltrate with prevalence of
macrophages. We have found the heterocomplex at different
levels in the synovial fluids of patients with active disease.
Additional studies aiming at evaluating the correlation between
the histologic pattern of the RA synovitis and the levels of the
CXCL12/HMGB1 heterocomplex in the joint fluids are needed,
and might reveal a preferential expression of the heterocomplex
in macrophage-rich infiltrates. If our hypothesis would be
confirmed, the heterocomplex might be used as a biomarker
of synovial inflammatory infiltrate arrangement, guiding novel
personalized therapeutic approaches.
Thus, the chemokine system remains a promising biological
target for the development of new therapeutic tools for
the treatment of chronic diseases, even if some limitations
hamper the efficacy of conventional competitive inhibitors.
The formation of heterocomplexes that enhance chemokine
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FIGURE 4 | Graphical abstract representing how the heterocomplex CXCL12/HMGB1 is maintained in active Rheumatoid Arthritis thanks to the activity of the
Thioredoxin system. The panel was created using Servier Medical Art according to Creative Commons Attribution 3.0 Unported License (https://creativecommons.
org/licenses/by/3.0/). Changes were made to the original cartoons.
activities calls for innovative approaches (56, 57). Novel data
indicate that CXCL12/HMGB1 promotes tissue regeneration
(23, 24), and together with the present findings demonstrate
how diverse can be the activity of the heterocomplex if
associated to tissue damage or to a state of cell activation in
the presence of a pathological condition. Tissue regeneration
and tissue damage could be also part of the same disease,
like suggested for Ankylosing Spondylitis (AS), where spinal
bone formation occurs as a post-inflammation tissue remodeling
reaction rather than an uncoupled process from inflammation
(58). Future studies will clarify if post-inflammation tissue
remodeling reactions could be ascribed to the activity of this
heterocomplex. The specific conformational changes induced
in CXCR4 by the heterocomplex (21), the prevention of
CXCL12 degradation when the chemokine is complexed with
HMGB1 (59), the various signaling cascades triggered by the
heterocomplex in active RA, all need consideration when novel
therapeutic strategies for chronic inflammatory diseases will be
exploited.
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